My address on South Korea's role in the Development of the Vaccine industry at the International Vaccine Industry Forum on September 22, 2017 at Andong City, South Korea.
Back care and back massage. powerpoint presentation
International vaccine industry forum 2017 22 09-17
1. 1
S.Korea’s Role in Emerging & Developing Vaccine Market
Opportunities for Growth through Collaboration with International Vaccine Industry
Trends in Developing Countries Vaccine Markets
Andong City, S. Korea
22-09-2017
Dr Rajesh Jain
Jt. Managing Director, Panacea Biotec
New Delhi, India
2. Contents
Growing Synergies : Cultural, Political & Bilateral Trade
India: Opportunities, Make in India & Korea Plus
Strengthening India & Korea business relations
Vaccine Market & Initiatives to boost
Collaboration in Vaccine Space
Vaccine Market Selfie
An Invitation
2
3. India & South Korea were ruled by other country & share
common Independence day !
India : 15 August 1947
S. Korea : 15 August 1945
Both India & South Korea are Democratic Countries
Both India & South Korea are Peace Loving & Progressive Countries
India & South Korea tied diplomatic ties way back in 1973 & several
Trade Agreements have been signed
3
Cordial relationship between the two
countries extends back to 48AD, when
Queen Suro, or Princess Heo Hwang-ok,
travelled from the kingdom of Avodhya
in North India to Korea.
India & S Korea are both tied with a strong Asian Cultural Thread
Buddhism continues to bind India &
South Korea
Both Indian & South Korean calendar
are based on Lunisolar system.
Like Indians, Korean name comprises
of given name & surnames. In Indian
& Korean Cultures Girl & boys from
same family name (Gotra) are
prohibited to marry each other.
Family
Name
&
Marriage
Cultural Political
India–South Korea relations have been relatively strong for 2,000 years, although more progress arose during the past three decades.
4. US$530 million
1992-1993
US$10 billion
2006-2007
USD 16.83 billion
2016-17
India and South Korea reviewed their free trade
agreement to further boost bilateral trade and
investment in July 2017.
The Comprehensive Economic Cooperation
Agreement (CEPA) signed between the two
countries, provides an excellent platform for
expanding the bilateral trade, which is currently
below its potential, and also give great impetus
for flow of investment both ways.
Bilateral Trade between the two Nations has increased
exponentially in last 25 years
4
India's imports from South Korea during 2016-17 stood at USD 12.59 Bn, while
exports were at USD 4.24 Bn. Advantage Korea!
India received USD 2.26 billion foreign direct investment from South Korea
between March 2000 and April 2017!
5. Growing Synergies Between India And South Korea
5
In 2015, during Indian Prime Minister’s
visit, India & South Korea signed seven
agreements to boost cooperation with
a result: Bilateral Ties raised to
Strategic Partnership!
2010
In July 2017, Indian PM met H.E. Mr Moon Jae-
in President, Republic of Korea and extended
felicitations in person for his victory in
Presidential election.
Both leaders expressed their commitment to
further develop the special strategic
partnership between India and South Korea,
particularly through participation in
programmes such as Make in India, Digital
India, Start up India, etc
The Prime Minister invited President Moon to
visit India at an early date.
"we consider South Korea a crucial partner in
India's economic modernization".
Mr Modi said, during his visit to South Korea in 2015
In May, 2017 Mr Modi’s congratulatory phone call to H.E. Mr Moon Jae-in,
upon his election as President of the Republic of Korea and tweet in Korean
language, was warmly received by the people of South Korea.
Indian Prime Minister Mr. Narendra Modi & H.E Mr Moon Jae-in during G20 Summit
6. Initiatives taken to boost
S Korean Market
S Korea’s spending on R&D is projected to be 25% higher at 5% of its GDP in 2017.
6
• S Korean Govt. plans to make Korea fifth largest producer of vaccines by 2020.
• In April 2017, The Ministry of Health & Welfare, Korea and the International Vaccine
Institute (IVI) signed a MOU on a collaboration to advance global public health, and
vaccine development and delivery cooperation.
• The Ministry of Food and Drug Safety presented a plan to expand varieties of
domestically-produced vaccines from 10 to 22 by 2020, in order to enhance the
self-sufficiency of vaccine
• Investments on R&D in Korea exceed US, Europe, Japan & China.
7. Korean Vaccine Companies and their Achievements
• SK Chemicals :
1. Expanding its global business territory with its advanced vaccine R&D technologies and production capability.
2. ‘SKYCellflu Quadrivalent’ being a globally first Tetravalent Flu vaccine!
3. Signed an agreement with PATH for Co-development and manufacturing of next-generation rotavirus vaccine
• Green Cross :
1. 7 Products in R&D Pipeline
2. 50% Flu Vaccine Market Share. Inked a massive $32 million contract to export its flu vaccines to the Pan American Health
Organization (PAHO) of the World Health Organization.
3. Tetanus-Diphtheria (Td) Vaccine Wins Approval in March 2017.
4. In January, 2017, Green Cross secured a $60 million order to supply its varicella vaccine to PAHO from 2017-2018.
5. Signed a memorandum of understanding with the International Vaccine Institute to jointly develop a vaccine to prevent
Zika virus
• LG Chemicals:
1. Pre-qualified manufacturer & supplier of Pentavalent Vaccines to UN Agencies
2. One of the first two companies in DCVMN to be recipient of sIPV technology from Intravacc, The Netherlands
3. Received US$12.6 million from Bill Gates Foundation for sIPV Vaccine development, In June 2017.
• IVI: 1. In April 2017, The Ministry of Health & Welfare, Korea and the International Vaccine Institute (IVI) signed a MOU on a
collaboration to advance global public health, and vaccine development and delivery cooperation.
2. In August 2017, The Indian Council of Medical Research (ICMR) has entered into an agreement to collaborate on vaccine
research and development combatting various infectious diseases.
7
8. India: The Land of Opportunities!
8
Projected common market with a GDP of US$ 2 Trillion, Thanks to GST implementation
A strong population of 1.2 billion & growing!
Korea being a developed economy equipped with determination, hard work, entrepreneurship and risk taking
capabilities, can play a significant role in India’s Make in India initiative
500 Korean companies are already doing business in India!
Can Korea become India’s potential business partner to help India increase its manufacturing growth from
current 16% to 25% to country’s GDP?
Now the key question is:
9. Make in India: Excellent Track Record of Korean Companies
9
Post 1992, Korea’s export growth model coupled with India’s economic liberalization made for the perfect
synergy for Korea to enter Indian Market Successfully.
Samsung: The No.1 brand in Mobile phones in India, a Responsible Enterprise!
Hyundai: The No. 2 Automobile Company in India having manufactured & sold 7.5million cars and
exported 2.2million “Made in India” cars all over the world till date.
Most Preferred Cars in India!
LG: Life is Good! Household brand name in India in white goods!! Trusted in aftersales Service!!!
10. Strengthening India –Korea Business Relations
The Government of India launched Korea Plus, a special initiative to promote
and facilitate Korean Investments in India.
The mandate of Korea Plus covers the entire investment spectrum including:
Supporting Korean enterprises entering the Indian market for the first time.
Looking into issues faced by Korean companies doing business in India
Policy advocacy to the Indian Government on Korean companies behalf.
Korea Plus will act as a mediator in arranging meetings, assisting in public
relations and research/evaluation and provide information and counseling in
regard to Korean companies’ investing in India.
http://pib.nic.in/newsite/PrintRelease.aspx?relid=14630510
India and the Republic of Korea relations have made great strides in recent years and Korea Plus will act as a
catalyst in making these relations even more robust.
.
11. Highest WHO Rating of Indian NRA
• In Feb 2017, WHO gave highest rating for vaccine
regulations to National Regulatory Authority of India
which will deepen the resolve to maintain the
highest quality and efficacy of the products that are
manufactured within country.
• The renewed confidence in India’s NRA allows the
domestic vaccine manufacturers to apply for WHO
vaccine prequalification programme.
• It also allows export of Indian vaccines to the world
immunization market, and will probably lead to more
affordable vaccines.
• The development is also supportive of the ‘Make in
India’ initiative.
11
A World Health Organization (WHO) led team of international
experts from countries has affirmed that the National Regulatory
Authority of India (NRA) and affiliated institutions meet the WHO
published indicators for a functional vaccine regulatory system.
12. India on Global Innovation Index, 2016
Sourcr: Global Innovation Index organisation, Business standard, The Hindu12
India scored a major improvement
in its Global Innovation Index
ranking in 2016, moving up to the
66th place from 81 in 2015
India's better performance in the
latest index readings was due to its
strengths in tertiary education,
software exports, corporate R&D and
market sophistication
The Commerce Minister also
announced setting up of a taskforce on
innovation, to suggest new ideas on
best way forward in inculcating an
innovative temperament in the
country.
Chandrajit Banerjee, Director General
of Confederation of Indian Industry
(CII) says:
“The commitment of India to
innovation and improved innovation
metrics is strong and growing, helping
to improve the innovation
environment. This trend will help
gradually lift India closer to other top-
ranked innovation economies”,
13. Innovation in India: An Opportunity for Collaboration!
13
Source: pharmafocusasia
The journey from Generics to Innovation has just begun! The spirit of collaborationdrives the journey
The willingness and
capacity to take risks
will fuel the growth!
GROWTH
The enabling policy
framework provides the
building blocks and
facilitates the journey!!!
FACILITATION
The technical education,
access to skilled manpower
& their exposure to global
multinationals acting as
catalysts !!
CATALYSTS
100% foreign ownership and full repatriation of capital and profits
R&D programs under the chapter of trade in services of WTO
Large pool of English speaking skilled manpower with Strong Technical capabilities
Telecom infrastructure & Geographical location enabling 24x7 service offerings
Good regulatory framework & Favourable tax regime for R&D with IPR protection
14. Panacea Biotec: An Overview
• 25 Branded Products in more than 35 countries
• India’s 2nd largest Vaccine producer & 3rd largest
Biotechnology company
• Among top 25 Pharma companies in its represented
market in India
• 121 Mn children protected from various diseases like Polio, Diphtheria, Pertussis,
Hepatitis B, Haemophillus Influenza type B etc. - by supplying affordable vaccines.
• Millions of Diabetic, Cancer, Transplant (Kidney, Liver, Heart) Patients treated with
Affordable Quality medicines manufactured by Panacea Biotec.
Contributed in Polio Eradication
Supplied over 10 billion doses of Polio Vaccine in
partnership with Government of India, UNICEF, GAVI, Bill
& Melinda Gates Foundation
Several Cutting Edge Technologies in pipeline:
Vaccines - aP based combinations, Pneumococcal Conjugate Vaccine & Dengue Vaccine
Pharmaceuticals & Biosimilars – Paclitaxel Nanoparticles, Doxorubicin Liposomes, DPO, Trastuzumab
Core Business : Pharmaceuticals, Vaccines, Biosimilars & Health Supplements
Confidential
15. Innovation Capabilities
GRAND : Platform Drug Delivery Systems
• Focus areas : Nanoparticles, Liposomes, Microparticles,
Gastroretentive Systems, Oral films
Sampann : Molecule Specific Drug Delivery Systems, Generics
• Focus areas : Oral modified release, SMEDDS in softgels,
Transdermal, MD tablets, High barrier to entry generics
Laksh : Drug Discovery Small Molecules
• Target identification to development of pre-clinical candidate
• Focus areas : Metabolic disorders, Anti-infectives, CNS
• 4 NCEs in development
Onestream : Biosimilars, Vaccines
• Target identification to development of pre-clinical candidate
• Biosimilars :
Darbepoetin Alfa, Trastuzumab, Bevacizumab, Rituximab
• Vaccines : Pneumococcal, Dengue
Confidential
16. Global Footprint
Corporate HQ, R&D, Manufacturing, Marketing & Sales
India
Direct Presence through Wholly owned subsidiary
Germany
Partnership & Alliances
North America, Europe, ANZ & Canada
Distributors with Panacea’s Field Team
Russia CIS, Asia & Other ROW markets
SerbiaBosnia
Germany
Kazakhstan
Belarus
Ukraine
Russia
Syria
Vietnam
Thailand
Sri-lanka
Kenya
US
Australia
New Zealand
Philippines
Myanmar
Uganda
Nigeria
Tanzania
Mongolia
Cambodia
Singapore
Hong Kong
Algeria
Morocco
India
Brazil
Switzerland
Turkey
Confidential
20. 20 * Patented by Panacea Biotec
Value creation through Collaboration
A Successful Business Model
IPV
BBio, The Netherlands
Hep B
Heber Biotech, Cuba
DTP
Biopharma, Indonesia
Hib
Novartis, Switzerland
Formulation Development by
Panacea Biotec, India
Formulation Development by
Panacea Biotec, India
&
EasySix*
(DTwP - HepB - Hib - IPV)
EasyFive
(DTwP - HepB - Hib)
Ecovac4 & EasyFour
(DTwP - HepB) (DTwP - Hib)
HepB, DTP & Hib
Panacea Biotec, India
21. Value Creation through Collaboration
Tetravalent Dengue Vaccine Development
21
NIH, USA
Antigens
Panacea Biotec
Formulation
Development & Clinical
Trails
Regulatory
Process
Regulatory
Process
Butantan, Brazil
Formulation
Development & Clinical
Trails
22. Opportunities for Collaboration in Vaccine Space
1. Vaccines:
i. DTwP-IPV based Hexavalent Vaccines
ii. DTaP-IPV based Combination Vaccines
iii. HPV
iv. Rotavirus Vaccine
v. Typhoid Conjugate Vaccine
vi. MMR-V
vii. Td vaccine
viii. RSV vaccine
2. Blood Products:
i. Human Albumin
ii. Factor VIII
3. Monoclonal Antibodies
22
23. Vaccine Market Selfie
New Vaccine
Adequate Supply
Timely
Lowest Price
Healthy Market
Good Quality
Wow
Too Good To be True
WowWow
Continuous
Improvement
24. An Invitation
24
India invites South Korean Vaccine Companies to come forward for a bigger collaboration with Indian
counterparts to leverage innovation and exploit the untapped Market Potential in the Developing
Countries!
